Insmed Incorporated (NASDAQ:INSM) Position Boosted by Deutsche Bank AG

Deutsche Bank AG raised its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 76.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 488,966 shares of the biopharmaceutical company's stock after buying an additional 212,024 shares during the quarter. Deutsche Bank AG owned about 0.27% of Insmed worth $33,758,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Capital CS Group LLC acquired a new stake in shares of Insmed during the 4th quarter valued at approximately $586,000. Park Avenue Securities LLC lifted its position in shares of Insmed by 42.1% in the 4th quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company's stock worth $549,000 after buying an additional 2,358 shares during the last quarter. Atomi Financial Group Inc. boosted its holdings in shares of Insmed by 6.6% in the 4th quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company's stock valued at $1,710,000 after buying an additional 1,526 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Insmed by 5.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock valued at $244,000 after buying an additional 183 shares during the period. Finally, Avior Wealth Management LLC bought a new stake in shares of Insmed during the 4th quarter valued at about $157,000.

Insmed Stock Down 3.0%

INSM opened at $65.71 on Wednesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company has a market capitalization of $11.95 billion, a PE ratio of -11.75 and a beta of 0.84. The stock's fifty day moving average is $72.17 and its 200-day moving average is $73.26. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same quarter last year, the firm posted ($1.06) earnings per share. Insmed's revenue was up 22.9% compared to the same quarter last year. On average, equities analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Sara Bonstein sold 18,322 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the completion of the sale, the chief financial officer now directly owns 118,863 shares of the company's stock, valued at $9,545,887.53. This trade represents a 13.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO William Lewis sold 6,830 shares of the business's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $72.57, for a total value of $495,653.10. Following the sale, the chief executive officer now directly owns 233,924 shares in the company, valued at $16,975,864.68. This trade represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 88,232 shares of company stock worth $6,868,473 in the last ninety days. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. UBS Group cut their target price on shares of Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Truist Financial increased their target price on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Guggenheim restated a "buy" rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $94.63.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.